CHARLES J LINK, MD
Osteopathic Medicine in Des Moines, IA
License number
Iowa 29516
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
1221 Medical Oncology And Hematology STE 100, Des Moines, IA 50309
Phone
(515) 282-2921
(515) 282-1035 (Fax)
(515) 282-1035 (Fax)
Organization information
See more information about CHARLES J LINK at bizstanding.comCHARLES J. LINK, M.D., PC
1221 Pleasant STE #100, Des Moines, IA
Registration:
Feb 3, 2000
State ID:
237285
Business type:
C DOMESTIC PROFESSIONAL
Expiration:
PERPETUAL
Agent:
Ronald R. Ricker ,1900 Hub Twr 699 Walnut St , Des Moines, IA (Physical)
Professional information
Dr. Charles J Link, Des Moines IA - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
Des Moines Office
411 Laurel St STE A300, Des Moines 50314
(515) 247-3970 (Phone), (515) 643-8819 (Fax)
411 Laurel St STE A300, Des Moines 50314
(515) 247-3970 (Phone), (515) 643-8819 (Fax)
Certifications:
Internal Medicine, 1989, Medical Oncology, 1991
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Des Moines Office
411 Laurel St STE A300, Des Moines 50314
Mercy Medical Center - Des Moines
1111 6Th Ave, Des Moines 50314
411 Laurel St STE A300, Des Moines 50314
Mercy Medical Center - Des Moines
1111 6Th Ave, Des Moines 50314
Education:
Medical School
Stanford University School Of Medicine
Graduated: 1985
Moffitt Hospital University Of Ca
Nci
Stanford University School Of Medicine
Graduated: 1985
Moffitt Hospital University Of Ca
Nci
Charles J Link, Des Moines IA
Specialties:
Internal Medicine, Hematology & Oncology, Hematology, Medical Oncology
Work:
Medical Oncology & Hematology Associates
1221 Pleasant St, Des Moines, IA 50309 Medical Oncology & Hemotology
411 Laurel St, Des Moines, IA 50314
1221 Pleasant St, Des Moines, IA 50309 Medical Oncology & Hemotology
411 Laurel St, Des Moines, IA 50314
Education:
Stanford University (1985)
Charles J Link, Des Moines IA
Specialties:
Internist
Address:
1221 Pleasant St, Des Moines, IA 50309
11043 Aurora Ave, Urbandale, IA 50322
11043 Aurora Ave, Urbandale, IA 50322
Education:
Stanford University, School of Medicine - Doctor of Medicine
National Institutes of Health-Clinical Center - Fellowship - Oncology (Internal Medicine)
UCSF Medical Center - Residency - Internal Medicine
National Institutes of Health-Clinical Center - Fellowship - Oncology (Internal Medicine)
UCSF Medical Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Enhanced Immunogenicity Of Tumor Associated Antigens By Addition Of Αgal Epitopes
US Patent:
8357777, Jan 22, 2013
Filed:
Jun 30, 2011
Appl. No.:
13/173692
Inventors:
Mario R. Mautino - Ankeny IA, US
Nicholas N. Vahanian - Polk City IA, US
Won-Bin Young - Pittsburgh PA, US
Gabriela Rossi - Ankeny IA, US
Charles J. Link - Clive IA, US
Firoz Jaipuri - Ames IA, US
Nicholas N. Vahanian - Polk City IA, US
Won-Bin Young - Pittsburgh PA, US
Gabriela Rossi - Ankeny IA, US
Charles J. Link - Clive IA, US
Firoz Jaipuri - Ames IA, US
Assignee:
Newlink Genetics - Ames IA
International Classification:
A61K 38/16
US Classification:
530345, 530300, 530350
Abstract:
The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epi topes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
Enhanced Immunogenicity Of Tumor Associated Antigens By Addition Of Alphagal Epitopes
US Patent:
2013016, Jun 27, 2013
Filed:
Dec 17, 2012
Appl. No.:
13/716570
Inventors:
Nicholas N. Vahanian - Polk City IA, US
Won-Bin Young - Pittsburgh PA, US
Gabriela Rossi - Ankeny IA, US
Charles J. Link - Clive IA, US
Firoz Jaipuri - Ames IA, US
Won-Bin Young - Pittsburgh PA, US
Gabriela Rossi - Ankeny IA, US
Charles J. Link - Clive IA, US
Firoz Jaipuri - Ames IA, US
Assignee:
NewLink Genetics Corp. - Ames IA
International Classification:
A61K 39/00
US Classification:
4241931
Abstract:
The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
Method For High Throughput Elucidation Of Transcriptional Profiles And Genome Annotation
US Patent:
2004019, Sep 30, 2004
Filed:
Mar 26, 2004
Appl. No.:
10/810976
Inventors:
Won-Bin Young - Ames IA, US
Charles Link - Des Moines IA, US
Charles Link - Des Moines IA, US
International Classification:
C12Q001/68, C12P019/34, C12N015/85
US Classification:
435/091200, 435/455000
Abstract:
The invention relates to methods for the elucidation of a transcriptional profile of a cell and for methods to facilitate functional genome annotation. The method of this invention relies on random integration of an artificial exon or a nucleotide fragment that tags the RNA of the gene into which it integrates. In eukaryotic cells, it allows the simultaneous identification of exon-intron boundaries for genome annotation. The gene trapping based strategy for transcript tagging is followed by recovery of those tags fused to flanking cellular exon sequences. Polymerization of those tags allows for high-throughput sequencing and characterization of exon-intron boundaries. Moreover, determination of the frequencies of each particular tag is used to determine the relative transcriptional level of each tagged RNA variant.
Enhanced Immunogenicity Of Tumor Associated Antigens By Addition Of Alphagal Epitopes
US Patent:
2013017, Jul 11, 2013
Filed:
Dec 17, 2012
Appl. No.:
13/716569
Inventors:
Nicholas N. Vahanian - Polk City IA, US
Won-Bin Young - Pittsburgh PA, US
Gabriela Rossi - Ankeny IA, US
Charles J. Link - Clive IA, US
Firoz Jaipuri - Ames IA, US
Won-Bin Young - Pittsburgh PA, US
Gabriela Rossi - Ankeny IA, US
Charles J. Link - Clive IA, US
Firoz Jaipuri - Ames IA, US
Assignee:
NewLink Genetics Corp. - Ames IA
International Classification:
C07H 5/04
US Classification:
536 53
Abstract:
The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
Method For Tumor Treatment Using Infusion Of Xenogeneic Cells To Induce Hyperacute Rejection And Innocent Bystander Effect
US Patent:
2006003, Feb 16, 2006
Filed:
Sep 8, 2005
Appl. No.:
11/221515
Inventors:
Charles Link - Clive IA, US
Tatiana Seregina - West Des Moines IA, US
Tatiana Seregina - West Des Moines IA, US
Assignee:
Human Gene Therapy Research Institute - Des Moines IA
International Classification:
A61K 48/00, A61K 39/395
US Classification:
424093210, 424146100, 514044000
Abstract:
A method for treating tumors. Through infusion or xenotransplantation of xenogeneic cells, such as infusion of murine cells into the peritoneal cavity of humans, a hyperacute rejection response to the cells is induced. This in turn creates a bystander effect to the tumor. This effect creates tumor regression. This treatment can be used alone or in conjunction with gene therapy or chemotherapy treatments.
Methods And Compositions For Elucidating Relative Protein Expression Levels In Cells
US Patent:
6897020, May 24, 2005
Filed:
Mar 19, 2001
Appl. No.:
09/811842
Inventors:
Charles J. Link - Des Moines IA, US
Tatiana Seregina - Ames IA, US
Nicholas N. Vahanian - Ames IA, US
James N. Higginbotham - Ames IA, US
W. Jay Ramsey - Ames IA, US
Bradley J. Powers - Ames IA, US
Sachet A. Shukla - Ames IA, US
Won Bin Young - Ames IA, US
Tatiana Seregina - Ames IA, US
Nicholas N. Vahanian - Ames IA, US
James N. Higginbotham - Ames IA, US
W. Jay Ramsey - Ames IA, US
Bradley J. Powers - Ames IA, US
Sachet A. Shukla - Ames IA, US
Won Bin Young - Ames IA, US
Assignee:
NewLink Genetics Inc. - Ames IA
International Classification:
C12Q001/68
US Classification:
435 6, 435 691, 435463, 4353201
Abstract:
The present invention relates generally to methods and compositions for the identification of differential protein expression patterns and concomitantly the active genetic regions that are directly or indirectly involved in different tissue types, disease states, or other cellular differences desirable for diagnosis or for targets for drug therapy.
Methods And Compositions For Efficient Gene Transfer Using Transcomplementary Vectors
US Patent:
6875610, Apr 5, 2005
Filed:
May 31, 2001
Appl. No.:
09/871183
Inventors:
James N. Higginbotham - Ames IA, US
Charles J. Link - Des Moines IA, US
William J. Ramsey - Ames IA, US
Charles J. Link - Des Moines IA, US
William J. Ramsey - Ames IA, US
Assignee:
Human Gene Therapy Research Institute - Des Moines IA
International Classification:
C12N015/861, C12N015/63, C12N015/64, C12N005/10, C07H021/04
US Classification:
435457, 4353201, 435455, 435456, 435325, 435 691, 536 231, 536 235, 536 232, 536 237, 536 241
Abstract:
The invention includes a viral vector method and composition comprising transcomplementary replication incompetent viral vectors, preferably adenoviral vectors, which are cotransformed to a recipient cell. The two vectors complement each other and thus allow viral replication, in a synergistic combination which enhances both gene delivery and gene expression of genetic sequences contained within the vector.